

# Resource Summary Report

Generated by [RRID](#) on Aug 30, 2026

## Huh-7.5

RRID:CVCL\_7927

Type: Cell Line

### Proper Citation

RRID:CVCL\_7927

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_7927](https://web.expasy.org/cellosaurus/CVCL_7927)

**Proper Citation:** RRID:CVCL\_7927

**Description:** Cell line Huh-7.5 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Male

**Disease:** Adult hepatocellular carcinoma

**Defining Citation:** [PMID:12438626](#), [PMID:15708988](#), [PMID:17079281](#), [PMID:17552027](#), [PMID:25768906](#), [PMID:27929099](#), [PMID:29468137](#), [PMID:30504788](#)

**Comments:** Virology: Highly susceptible to infection by Zika virus (ZIKV) (PubMed=29468137)., Virology: Highly permissive for hepatitis C virus (HCV) replication., Population: Japanese., Part of: ENCODE project common cell types; tier 3.

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** Huh-7.5

**Synonyms:** Huh 7.5, Huh7.5

**Cross References:** BTO:BTO\_0004126, EFO:EFO\_0005704, BioGRID\_ORCS\_Cell\_line:1220, cancercellines:CVCL\_7927, ENCODE:ENCBS227AAA, GEO:GSM816671, GEO:GSM2247740, GEO:GSM2247741, GEO:GSM2247742, Lonza:1432, PRIDE:PXD006386, Wikidata:Q54896856

**ID:** CVCL\_7927

**Hierarchy:** cvcl\_0336

**Record Creation Time:** 20220427T220622+0000

**Record Last Update:** 20260829T234258+0000

---

## Ratings and Alerts

No rating or validation information has been found for Huh-7.5.

No alerts have been found for Huh-7.5.

---

## Data and Source Information

**Source:** [CelloSaurus](#)

---

## Usage and Citation Metrics

We found 1057 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Chaput S, et al. (2026) Preclinical efficacy of a favipiravir and nitazoxanide combination against Rift Valley Fever Virus. *Antiviral research*, 249, 106402.

Clark JJ, et al. (2026) Cross-binding antibodies capable of neutralising diverse hantaviruses are produced in response to Puumala virus infection. *EBioMedicine*, 106091.

Pasquero S, et al. (2026) Targeting peptidyl-arginine deiminase 4 suppresses SARS-CoV-2 replication and modulates the inflammatory response. *iScience*, 29(3), 115038.

Nelson AN, et al. (2025) STAT1-mediated interferon signaling in the hematopoietic system is essential for restricting Usutu virus infection in vivo. *PLoS neglected tropical diseases*, 19(7), e0013317.

Szostek O, et al. (2025) The HCV-Dependent Inhibition of Nrf1/ARE-Mediated Gene Expression Favours Viral Morphogenesis. *Viruses*, 17(8).

Abiona OM, et al. (2025) MERS-CoV spike vaccine-induced N-terminal domain-specific antibodies are more protective than receptor binding domain-specific antibodies. *iScience*, 28(2), 111632.

Catanzaro NJ, et al. (2025) ACE2 from *Pipistrellus abramus* bats is a receptor for HKU5 coronaviruses. *Nature communications*, 16(1), 4932.

Pereira CM, et al. (2025) Bothropstoxins I and II as potent phospholipase A2 molecules from *Bothrops jararacussu* to impair hepatitis C virus infection. *Biochimie*, 235, 39.

Chaput S, et al. (2025) Assessing human liver spheroids as a model for antiviral drug evaluation against BSL-3 haemorrhagic fever viruses. *Antiviral research*, 239, 106188.

Joshi G, et al. (2025) Plasmacytoid dendritic cell sensing of hepatitis E virus is shaped by both viral and host factors. *Life science alliance*, 8(6).

Mazeaud C, et al. (2024) Zika virus remodels and hijacks IGF2BP2 ribonucleoprotein complex to promote viral replication organelle biogenesis. *eLife*, 13.

Khalfi P, et al. (2024) Comparative analysis of human, rodent and snake deltavirus replication. *PLoS pathogens*, 20(3), e1012060.

Sama B, et al. (2024) The effects of Remdesivir's functional groups on its antiviral potency and resistance against the SARS-CoV-2 polymerase. *Antiviral research*, 232, 106034.

Lin S, et al. (2023) Hepatitis E Virus: Isolation, Propagation, and Quantification. *Current protocols*, 3(1), e642.

Alzua GP, et al. (2023) Identification of novel neutralizing determinants for protection against HCV. *Hepatology (Baltimore, Md.)*, 77(3), 982.

Alzua GP, et al. (2023) Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in mice. *Gut*, 72(3), 560.

Thoresen DT, et al. (2023) A rapid RIG-I signaling relay mediates efficient antiviral response. *Molecular cell*, 83(1), 90.

Zhang C, et al. (2023) Sorafenib/2800Z Co-Loaded into Cholesterol and PEG Grafted Polylysine NPs for Liver Cancer Treatment. *Pharmaceuticals (Basel, Switzerland)*, 16(1).

Chen S, et al. (2023) NS5A domain I antagonises PKR to facilitate the assembly of infectious hepatitis C virus particles. *PLoS pathogens*, 19(2), e1010812.

Sekrecka A, et al. (2023) Time-dependent recruitment of GAF, ISGF3 and IRF1 complexes shapes IFN $\gamma$  and IFN $\alpha$ -activated transcriptional responses and explains mechanistic and functional overlap. *Cellular and molecular life sciences : CMLS*, 80(7), 187.